Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Charleston Oncology

Neither a doctor nor a teaching hospital

Research payments

$807,469

261 payments

Through program year 2024, Charleston Oncology is reported as receiving $807,469 in research payments, across 261 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $4,805 2
2023 Research $59,506 13
2022 Research $105,595 39
2021 Research $173,996 38
2020 Research $317,643 103
2019 Research $145,923 66

Breakdown

Who paid Research payments · program years 2019–2024
  1. Merck Sharp & Dohme Corporation $488,000 112 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $147,500 30 payments
  3. Amgen Inc. $67,776 29 payments
  4. Sanofi US Services Inc. $37,340 43 payments
  5. Regeneron Pharmaceuticals, Inc. $29,990 18 payments
  6. MorphoSys AG $12,050 1 payment
  7. AstraZeneca UK Limited $8,560 1 payment
  8. Chiesi USA, Inc. $6,300 1 payment
  9. Pharmacyclics LLC, An AbbVie Company $4,800 23 payments
  10. Incyte Corporation $4,500 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cisplatin as First-Line Therapy in Participants with Advanced and,or Unresectable Biliary Tract Carcinoma $149,731 9 payments
  2. A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cisplatin as First-Line Therapy in Participants with Advanced and,or Unresectable Biliary Tract Carcinoma $143,635 16 payments
  3. BAY 1841788 mHSPC $140,000 29 payments
  4. A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A Coformulated MK-1308,MK-3475 in Combination with Lenvatinib E7080,MK-7902 in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma $62,598 4 payments
  5. AMG 510_Ph3 NSCLC Monotherapy Comparator Trial $42,188 8 payments
  6. A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) $36,590 42 payments
  7. A Phase 4, single-arm, open-label clinical study of pembrolizumab MK-3475 to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent,metastatic head and neck squamous cell carcinoma KEYNOTE-B10 $32,214 3 payments
  8. Cemiplimab Survivorship Epidemiology (Case) Study $29,990 18 payments
  9. A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab,Vibostolimab Coformulation MK-7684A in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer MK-7684A-007,KEYVIBE-007 $28,639 1 payment
  10. A Phase 4, single-arm, open-label clinical study of pembrolizumab MK-3475 to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as firstline treatment of recurrent,metastatic head and neck squamous cell carcinoma KEYNOTEB10 $19,542 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record